KRAS and non-small cell lung carcinoma: A phase II trial is ongoing to determine the response rate of TVB-2640 in KRAS-mutant NSCLC patients by examining the RECIST and toxicity profile (ClinicalTrials.gov Identifier: NCT03808558).